Pharmacokinetics of sunitinib in hemodialysis.

@article{Izzedine2009PharmacokineticsOS,
  title={Pharmacokinetics of sunitinib in hemodialysis.},
  author={Hassane Izzedine and Marie-Christine Etienne-Grimaldi and Nicole Ren{\'e}e and St{\'e}phane Vignot and G{\'e}rard Milano},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2009},
  volume={20 1},
  pages={190-2}
}
Clear-cell renal carcinoma is the most common cancer of the kidney [1]. Up to 30% of patients with renal-cell carcinoma present with metastatic disease [2, 3] and recurrence develops in 40% of affected patients treated for a localized tumor [2, 4]. Long-term dialysis is a risk factor since prevalence in hemodialysis and renal transplant patients is 40–100 times higher than in the general population [6, 7]. Sunitinib is an orally administered inhibitor of tyrosine kinase targeting the vascular… CONTINUE READING
20 Citations
8 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Similar Papers

Loading similar papers…